首页> 外文期刊>Journal of minimally invasive gynecology >Use of the NovaSure Impedance Controlled Endometrial Ablation System in patients with intracavitary disease: 12-month follow-up results of a prospective, single-arm clinical study.
【24h】

Use of the NovaSure Impedance Controlled Endometrial Ablation System in patients with intracavitary disease: 12-month follow-up results of a prospective, single-arm clinical study.

机译:腔内疾病患者使用NovaSure阻抗控制的子宫内膜消融系统:前瞻性单臂临床研究的12个月随访结果。

获取原文
获取原文并翻译 | 示例
       

摘要

STUDY OBJECTIVE: To assess the safety and effectiveness of the NovaSure Impedance Controlled Endometrial Ablation System for the treatment of excessive uterine bleeding in premenopausal and postmenopausal women with intracavitary disease (polyps or myomas) up to 3 cm. DESIGN: Prospective, single-arm study. (Canadian Task Force Classification II-2.) SETTING: Academic medical center. PATIENTS: This clinical study was conducted in 65 women with menometrorrhagia with confirmed (type I and II) submucous myomas up to 3 cm with and without polyps. INTERVENTION: Patients were treated with the NovaSure System and received no hormonal or mechanical pretreatment to thin the endometrial lining or as a uterine pathologic condition shrinking agent. MEASUREMENTS AND MAIN RESULTS: All patients were diagnosed with intracavitary disease during office hysteroscopy. Patients completed menstrual questionnaires at the initial screening and at 1 year after treatment. Twelve-month results demonstrated that the NovaSure Systemwas effective in reducing excessive uterine blood loss. Success (defined as reduction to normal bleeding) was observed in 95% (95% CI: 86%-99%) of patients, with 69% (95% CI: 56%-80%) reporting amenorrhea at 1 year after treatment. The median treatment time (time of energy delivery) was 78 seconds (range 61-120 seconds). All patients underwent the procedure under local or intravenous sedation. No intraoperative or postoperative adverse events were reported. There was a significant decrease in premenstrual symptoms and dysmenorrhea at 12 months after the procedure. Ninety-five percent (95% CI: 86%-99%) of patients were satisfied with the procedure. CONCLUSION: Clinical results of this study demonstrate that the NovaSure System is safe and effective in treatment of patients with menometrorrhagia caused by intracavitary disease up to 3 cm.
机译:研究目的:评估NovaSure阻抗控制型子宫内膜消融系统用于治疗3厘米以内的腔内疾病(息肉或肌瘤)的绝经前和绝经后妇女过度子宫出血的安全性和有效性。设计:前瞻性单臂研究。 (加拿大工作队分类II-2。)地点:学术医学中心。患者:这项临床研究是针对65名经确诊(I型和II型)粘膜下肌瘤(不伴息肉和不伴息肉)的女性(不超过3 cm)进行的。干预:患者接受了NovaSure系统的治疗,未接受任何激素或机械预处理来使子宫内膜变薄或用作子宫病理性收缩剂。测量和主要结果:所有患者均在宫腔镜检查中被诊断为腔内疾病。患者在初筛时和治疗后1年完成月经问卷。十二个月的结果表明,NovaSure系统可有效减少过多的子宫失血。在治疗后1年,有95%(95%CI:86%-99%)的患者观察到成功(定义为减少正常出血),其中69%(95%CI:56%-80%)的妇女出现了闭经。中位治疗时间(能量输送时间)为78秒(范围为61-120秒)。所有患者均接受局部或静脉镇静。没有术中或术后不良事件的报道。术后12个月,经前症状和痛经明显减少。 95%(95%CI:86%-99%)的患者对该手术感到满意。结论:本研究的临床结果表明,NovaSure系统可安全有效地治疗由腔内疾病引起的月经不满3厘米的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号